{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:12:21Z","timestamp":1782123141909,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970271"],"award-info":[{"award-number":["81970271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81670214"],"award-info":[{"award-number":["81670214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770253"],"award-info":[{"award-number":["81770253"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Atrial fibrillation (AF) is a common arrhythmia in patients with hypertension. ELABELA, which has cardioprotective effects, is decreased in the plasma of patients with hypertension and might be associated with AF in the hypertensive population. This study aims to measure the ELABELA plasma levels in hypertension patients with and without AF and to analyse the related factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 162 hypertension patients with or without AF were recruited for our monocentric observational study. Subjects were excluded if they had a history of valvular heart disease, rheumatic heart disease, cardiomyopathy, thyroid diseases, or heart failure. The patients\u2019 histories were recorded, and laboratory examinations were conducted. Plasma ELABELA was detected by immunoassay. Echocardiographs were performed, and parameters were collected by two experienced doctors. Binary logistic regression analysis was used to identify the association between ELABELA plasma level and AF in patients with hypertension.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Plasma ELABELA levels were lower in hypertension patients with AF than in those without AF (2.0 [1.5, 2.8] vs. 4.0 [3.4, 5.0] ng\/ml, P\u2009&lt;\u20090.001). ELABELA levels were correlated with age, heart rate, BNP levels and left atrial dimension. In addition to the left atrial dimension, ELABELA plasma levels were associated with AF in patients with hypertension (OR 0.081, 95% CI 0.029\u20130.224, P\u2009&lt;\u20090.001). ELABELA levels were further decreased in the persistent AF subgroup compared with the paroxysmal AF subgroup (1.8 [1.4, 2.5] vs. 2.2 [1.8, 3.0] ng\/ml, P\u2009=\u20090.012) and correlated with HR, BNP and ESR levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ELALABELA levels were decreased in hypertension patients with AF and further lowered in the persistent AF subgroup. Decreased ELABELA plasma levels were associated with AF in hypertension patients and may be an underlying risk factor.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-02197-x","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T07:07:15Z","timestamp":1628752035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Declined ELABELA plasma levels in hypertension patients with atrial fibrillation: a case control study"],"prefix":"10.1186","volume":"21","author":[{"given":"Zheng","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu-chang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-3761","authenticated-orcid":false,"given":"Xin-chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2197_CR1","first-page":"854","volume":"70","author":"MS Dzeshka","year":"2017","unstructured":"Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial Fibrill Hypertens Hypertens. 2017;70:854\u201361.","journal-title":"Atrial Fibrill Hypertens Hypertens"},{"key":"2197_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/2047487316676037","volume":"24","author":"B Gorenek Chair","year":"2017","unstructured":"Gorenek Chair B, Pelliccia Co-Chair A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, et al. European Heart Rhythm Association (EHRA)\/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur J Prev Cardiol. 2017;24:4\u201340.","journal-title":"Eur J Prev Cardiol"},{"key":"2197_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/ageing\/afq059","volume":"39","author":"B Pamukcu","year":"2010","unstructured":"Pamukcu B, Lip GYH, Lane DA. Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. Age Ageing. 2010;39:533\u20135.","journal-title":"Age Ageing"},{"key":"2197_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138:1093\u2013100.","journal-title":"Chest"},{"key":"2197_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","volume":"122","author":"P Verdecchia","year":"2018","unstructured":"Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res. 2018;122:352\u201368.","journal-title":"Circ Res"},{"key":"2197_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41440-018-0193-3","volume":"42","author":"Y Liu","year":"2019","unstructured":"Liu Y, Wang L, Shi H. The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia. Hypertens Res. 2019;42:928\u201334.","journal-title":"Hypertens Res"},{"key":"2197_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","volume":"251","author":"K Tatemoto","year":"1998","unstructured":"Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"2197_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.devcel.2013.11.002","volume":"27","author":"SC Chng","year":"2013","unstructured":"Chng SC, Ho L, Tian J, Reversade B. ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013;27:672\u201380.","journal-title":"Dev Cell"},{"key":"2197_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tips.2015.06.002","volume":"36","author":"P Yang","year":"2015","unstructured":"Yang P, Maguire JJ, Davenport AP. Apelin, Elabela\/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci. 2015;36:560\u20137.","journal-title":"Trends Pharmacol Sci"},{"key":"2197_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/10641963.2019.1619756","volume":"42","author":"Y Li","year":"2020","unstructured":"Li Y, Yang X, Ouyang S, He J, Yu B, Lin X, et al. Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function: a preliminary study. Clin Exp Hypertens. 2020;42:239\u201343.","journal-title":"Clin Exp Hypertens"},{"key":"2197_CR11","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"2197_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","volume":"50","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50:e1-88.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2197_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1124\/pr.119.017533","volume":"71","author":"C Read","year":"2019","unstructured":"Read C, Nyimanu D, Williams TL, Huggins DJ, Sulentic P, Macrae RGC, et al. International Union of Basic and Clinical Pharmacology. CVII. Structure and pharmacology of the apelin receptor with a recommendation that Elabela\/Toddler is a second endogenous peptide ligand. Pharmacol Rev. 2019;71:467\u2013502.","journal-title":"Pharmacol Rev"},{"key":"2197_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.21037\/atm.2020.02.07","volume":"8","author":"W Liu","year":"2020","unstructured":"Liu W, Yan J, Pan W, Tang M. Apelin\/Elabela-APJ: a novel therapeutic target in the cardiovascular system. Ann Transl Med. 2020;8:243.","journal-title":"Ann Transl Med"},{"key":"2197_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.peptides.2018.09.006","volume":"109","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wang Y, Lou Y, Luo M, Lu Y, Li Z, et al. Elabela, a newly discovered APJ ligand: similarities and differences with Apelin. Peptides. 2018;109:23\u201332.","journal-title":"Peptides"},{"key":"2197_CR16","doi-asserted-by":"publisher","first-page":"e17645","DOI":"10.1097\/MD.0000000000017645","volume":"98","author":"Y D\u00f6nmez","year":"2019","unstructured":"D\u00f6nmez Y, Acele A. Increased Elabela levels in the acute ST segment elevation myocardial infarction patients. Medicine. 2019;98:e17645.","journal-title":"Medicine"},{"key":"2197_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/eurheartj\/ehi648","volume":"27","author":"PT Ellinor","year":"2006","unstructured":"Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J. 2006;27:222\u20136.","journal-title":"Eur Heart J"},{"key":"2197_CR18","doi-asserted-by":"publisher","first-page":"5285392","DOI":"10.1155\/2018\/5285392","volume":"2018","author":"A Salska","year":"2018","unstructured":"Salska A, Dziuba M, Salski W, Chizynski K, Zielinska M. Apelin and atrial fibrillation: the role in the arrhythmia recurrence prognosis. Dis Markers. 2018;2018:5285392.","journal-title":"Dis Markers"},{"key":"2197_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/CIRCRESAHA.111.246876","volume":"110","author":"BJ North","year":"2012","unstructured":"North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res. 2012;110:1097\u2013108.","journal-title":"Circ Res"},{"key":"2197_CR20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.celrep.2017.10.057","volume":"21","author":"R Rai","year":"2017","unstructured":"Rai R, Ghosh AK, Eren M, Mackie AR, Levine DC, Kim S-Y, et al. Downregulation of the apelinergic axis accelerates aging, whereas its systemic restoration improves the Mammalian healthspan. Cell Rep. 2017;21:1471\u201380.","journal-title":"Cell Rep"},{"key":"2197_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cca.2018.10.011","volume":"487","author":"Q Zhou","year":"2018","unstructured":"Zhou Q, Chen L, Tang M, Guo Y, Li L. Apelin\/APJ system: a novel promising target for anti-aging intervention. Clin Chim Acta. 2018;487:233\u201340.","journal-title":"Clin Chim Acta"},{"key":"2197_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ygyno.2017.10.016","volume":"147","author":"Y Yi","year":"2017","unstructured":"Yi Y, Tsai S-H, Cheng J-C, Wang EY, Anglesio MS, Cochrane DR, et al. APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecol Oncol. 2017;147:663\u201371.","journal-title":"Gynecol Oncol"},{"key":"2197_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.stem.2015.04.002","volume":"16","author":"M Li","year":"2015","unstructured":"Li M, Gou H, Tripathi BK, Huang J, Jiang S, Dubois W, et al. An Apela RNA-containing negative feedback loop regulates p53-mediated apoptosis in embryonic stem cells. Cell Stem Cell. 2015;16:669\u201383.","journal-title":"Cell Stem Cell"},{"key":"2197_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010036","author":"L Jesel","year":"2019","unstructured":"Jesel L, Abbas M, Park S-H, Matsushita K, Kindo M, Hasan H, et al. Atrial fibrillation progression is associated with cell senescence burden as determined by p53 and p16 expression. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm9010036.","journal-title":"J Clin Med"},{"key":"2197_CR25","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.bbadis.2018.08.015","volume":"1865","author":"C Chi","year":"2019","unstructured":"Chi C, Li D-J, Jiang Y-J, Tong J, Fu H, Wu Y-H, et al. Vascular smooth muscle cell senescence and age-related diseases: state of the art. Biochimica et Biophysica Acta Mol Basis Dis. 2019;1865:1810\u201321.","journal-title":"Biochimica et Biophysica Acta Mol Basis Dis"},{"key":"2197_CR26","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/cvr\/cvx061","volume":"113","author":"T Sato","year":"2017","unstructured":"Sato T, Sato C, Kadowaki A, Watanabe H, Ho L, Ishida J, et al. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage. Cardiovasc Res. 2017;113:760\u20139.","journal-title":"Cardiovasc Res"},{"key":"2197_CR27","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1097\/CCM.0000000000002639","volume":"45","author":"D Coquerel","year":"2017","unstructured":"Coquerel D, Chagnon F, Sainsily X, Dumont L, Murza A, C\u00f4t\u00e9 J, et al. ELABELA improves cardio-renal outcome in fatal experimental septic shock. Crit Care Med. 2017;45:e1139\u201348.","journal-title":"Crit Care Med"},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.phrs.2017.10.007","volume":"128","author":"MS Kallistratos","year":"2018","unstructured":"Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacol Res. 2018;128:322\u20136.","journal-title":"Pharmacol Res"},{"key":"2197_CR29","first-page":"66","volume":"6","author":"Z Ma","year":"2020","unstructured":"Ma Z, Song J-J, Martin S, Yang X-C, Zhong J-C. The Elabela-APJ axis: a promising therapeutic target for heart failure. Heart Fail Rev. 2020;6:66.","journal-title":"Heart Fail Rev"},{"key":"2197_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcard.2012.02.009","volume":"165","author":"R Khatib","year":"2013","unstructured":"Khatib R, Joseph P, Briel M, Yusuf S, Healey J. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol. 2013;165:17\u201324.","journal-title":"Int J Cardiol"},{"key":"2197_CR31","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCRESAHA.114.302226","volume":"114","author":"J Heijman","year":"2014","unstructured":"Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114:1483\u201399.","journal-title":"Circ Res"},{"key":"2197_CR32","doi-asserted-by":"publisher","first-page":"F1122","DOI":"10.1152\/ajprenal.00606.2019","volume":"318","author":"C Xu","year":"2020","unstructured":"Xu C, Wang F, Chen Y, Xie S, Sng D, Reversade B, et al. ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury. Am J Physiol Renal Physiol. 2020;318:F1122\u201335.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2197_CR33","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.hlc.2017.05.119","volume":"26","author":"DH Lau","year":"2017","unstructured":"Lau DH, Linz D, Schotten U, Mahajan R, Sanders P, Kalman JM. Pathophysiology of paroxysmal and persistent atrial fibrillation: rotors, foci and fibrosis. Heart Lung Circ. 2017;26:887\u201393.","journal-title":"Heart Lung Circ"},{"key":"2197_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jcmg.2016.11.003","volume":"10","author":"L Thomas","year":"2017","unstructured":"Thomas L, Abhayaratna WP. Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance. JACC Cardiovasc Imaging. 2017;10:65\u201377.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2197_CR35","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1681\/ASN.2016111210","volume":"28","author":"H Chen","year":"2017","unstructured":"Chen H, Wang L, Wang W, Cheng C, Zhang Y, Zhou Y, et al. ELABELA and an ELABELA Fragment Protect against AKI. J Am Soc Nephrol. 2017;28:2694\u2013707.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02197-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02197-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02197-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T07:12:29Z","timestamp":1628752349000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02197-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02197-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"10 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by Beijing Chaoyang Hospital, and informed consent was collected from the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}